Strats SM Trust FOR U S Cell Corp SEC Series 2004 6 is a US-listed company in the commercial & residential mortgage finance industry. Its financial year ends in December.
The Fundamentalytics view
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Price chart
- 1 day-1.3%
- 1 week-0.7%
- 1 month+1.9%
- This year+1.3%
- 1 year+2.5%
- 5 years+23.7%
- S&P 500 this year+11.2%
Loading chart…
Third-party market data · may be delayed
At a glance
News & updates
Company announcements, filed results and changes that matter to shareholders.
No recent updates are available for GJH from the sources we follow. See filings →
No model value for Strats SM Trust FOR U S Cell Corp SEC Series 2004 6 at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.
Valuation models
We value Strats SM Trust FOR U S Cell Corp SEC Series 2004 6 as an asset manager, broker or exchange, with every model that fits that kind of business. Cost of equity 7.6%: the 10-year Treasury yield (4.9%) plus a beta of 0.6 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Price-to-book vs peers Book value per share times peers' typical (harmonic-mean) price-to-book. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Dividend discount (two-stage) Dividends for five years at the growth the business can fund, then a steady payout and growth. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. | — | No model applies: the filings don’t yet support a value. |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Strats SM Trust FOR U S Cell Corp SEC Series 2004 6 with asset managers, brokers and exchanges in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Forecasts and guidance
Analysts' consensus
No analyst estimates are published for Strats SM Trust FOR U S Cell Corp SEC Series 2004 6: too few analysts cover it.
Positioning
- Short interest
- — of tradable shares
- Days to cover
- — at average volume
- Short interest, 1 month
- —
- Held by institutions
- — of shares
- Held by insiders
- — of shares
Share-price performance
Market data may be delayedReturn and risk by year
| Calendar year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 to date |
|---|---|---|---|---|---|---|
| Return | ||||||
| GJH | +8% | −15% | +10% | +21% | +8% | +1% |
| Industry peers (median) | +5% | −11% | +12% | +6% | +6% | +2% |
| S&P 500 | +29% | −18% | +26% | +25% | +18% | +11% |
| Months that ended higher | ||||||
| GJH | 75% | 33% | 58% | 58% | 67% | 46% |
| S&P 500 | 75% | 42% | 67% | 75% | 75% | 46% |
| Largest fall from a high during the year | ||||||
| GJH | −4% | −21% | −20% | −11% | −5% | −5% |
| S&P 500 | −5% | −25% | −10% | −8% | −19% | −9% |
Worst fall since November 2, 2015: 37% from February 3, 2020 to March 18, 2020. Getting back needed a 58% gain, reached on June 11, 2020, 85 days after the low.
Price behaviour
- 52-week range
- $9.13 – $9.65
- From 52-week high
- −1.5%
- vs 50-day average
- +0.5%
- vs 200-day average
- +0.7%
- Volatility (1 year)
- 14%
- Beta vs S&P 500
- -0.10
Fundamentals
Insider trading activity
Full insider history and chartFrom insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Results announcements
Recent SEC filings
- 8-K Current report
- 10-K Annual report
- 8-K Current report
- 8-K Current report
- 10-K Annual report
- 8-K Current report
- 8-K Current report
- 10-K Annual report
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Strats SM Trust FOR U S Cell Corp SEC Series 2004 6 in brief
- What does Strats SM Trust FOR U S Cell Corp SEC Series 2004 6 do?
- Strats SM Trust FOR U S Cell Corp SEC Series 2004 6 is a US-listed company in the commercial & residential mortgage finance industry. Its financial year ends in December.
- What is Strats SM Trust FOR U S Cell Corp SEC Series 2004 6's stock ticker?
- Strats SM Trust FOR U S Cell Corp SEC Series 2004 6 trades under the ticker GJH on NYSE. This page brings together its financial statements, valuation models, ownership and recent company updates.
Follow research on Strats SM Trust FOR U S Cell Corp SEC Series 2004 6
New research on the companies we cover arrives in the weekly email. Free, one email a week.